Presentation Detail
Speaker
Sungwon Lim, PhD, CEO & Co-Founder of ImpriMed, Inc.
Synopsis
In this presentation, Dr. Sungwon Lim, CEO & Co-Founder of ImpriMed, shares the latest updates and new findings from ImpriMed. The key result includes that treatments predicted to be effective by ImpriMed’s artificial intelligence double the clinical response rate in relapsed B-cell lymphoma. Dr. Lim highlights successful cases that benefited from ImpriMed’s artificial intelligence-driven anticancer drug response predictions. ImpriMed’s flagship product, Personalized Prediction Profile, includes comprehensive diagnostic information and drug response predictions for canine blood cancers. ImpriMed’s artificial intelligence (AI) models, trained on real-world clinical outcome data, predict which anticancer drugs are most likely to be effective for a particular dog’s lymphoma or leukemia using the analytics of each patient’s live cancer cells.
